June 19, 2024 – Rutherrin®, has demonstrated an ability to provide a complete response in a Non-Small Cell Lung Cancer (“NSCLC”) animal model.

June 18, 2024 – Rutherrin®, in preclinical research, has demonstrated an ability to increase the efficacy of immunotherapy.

June 14, 2024 – Reminder Notice of Annual General and Special Meeting on June 19, 2024 at 4:30 pm after the formal part of the meeting a virtual zoom presentation will follow at 5:30 pm

June 12, 2024 – Rutherrin® has been proven in preclinical studies to enhance the efficacy of chemotherapy and reduce multidrug resistance.

June 10, 2024 – Ruvidar™, in combination with Bacillus Calmette-Guérin (BCG), significantly enhances the cancer cell-killing efficacy compared to BCG or Ruvidar™ alone, even without light activation.

June 6, 2024 – Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer (“NSCLC”).

June 4, 2024 – Theralase’s lead compound, Ruvidar, has been proven effective in the inactivation of various viruses. The research was completed at the laboratory of Kevin Coombs, Ph.D., University of Manitoba in conjunction with National Microbiology Laboratory and Theralase® Technologies Inc.

May 30, 2024 – Theralase releases the Company’s unaudited interim consolidated 1Q2024 Financial Statements

May 2, 2024 – Theralase expands its clinical team with the hiring of two Clinical Research Associates.

April 24, 2024 – Theralase closes Non-Brokered Private Placement of units for gross proceeds of $CAN 750,200.